Latest Articles
-
MRK Testing Price Floor: Time to Load Up?
Merck (MRK) should be on your watchlist. Here is why – it is currently trading in the support zone ($76.28 – $84.31), levels from which it has bounced meaningfully before. In the last 10 years, the stock received buying interest at th...
-
Will Merck Stock Rise On Its Upcoming Earnings?
Merck (NYSE:MRK) is scheduled to announce its earnings on Tuesday, July 29, 2025. Historically, MRK stock has shown a tendency for negative one-day returns following earnings announcements. Over the past five years, the stock experienced a declin...
-
Better Bet Than AbbVie Stock: Pay Less To Get More From Industry Peers
GILD, MRK are ABBV’s peers in Biotechnology industry that have: 1) Lower valuation (P/EBIT) compared to ABBV 2) But higher revenue and operating income growth This disconnect between valuation and performance could mean that you are bette...
-
Merck’s Latest Move: Why the Verona Deal Still Leaves Questions
Merck’s latest acquisition announcement sends a clear message about its urgency to address the looming Keytruda patent cliff. The pharmaceutical giant has agreed to purchase COPD drugmaker Verona Pharma for $10 billion, adding another poten...
-
Merck’s Upside Potential: Beyond The Keytruda Cliff
While Merck faces the inevitable Keytruda patent cliff in 2028, the company is positioning itself for continued growth through strategic diversification and pipeline expansion. Earlier this month, we discussed how Keytruda is a ticking time bomb ...
-
Merck’s Keytruda Dependency: A Growth Story With An Expiration Date
Merck’s (NYSE:MRK) leading drug, Keytruda, has shown remarkable recent growth—a success story with a foreseeable conclusion. The pharmaceutical company’s strong performance has been largely driven by Keytruda, a blockbuster oncology treatme...
-
What’s Next For Merck After A Q1 Beat?
Merck (NYSE: MRK) recently released its first-quarter results, surpassing Wall Street’s expectations for both revenue and earnings. The company reported revenue of $15.53 billion and adjusted earnings per share of $2.22, exceeding consen...
-
How Will Merck Stock React To Its Upcoming Earnings?
Merck (NYSE:MRK) is scheduled to release its earnings report on Thursday, April 24, 2025. Historical data suggests a potential negative reaction in MRK stock following the announcement. Over the past five years, the stock has experienced a nega...
-
Market Turmoil? Look At Healthcare Dividend Stocks With 3%+ Yields
The S&P 500’s 9% decline in 2025, triggered by President Trump’s tariffs and heightened trade tensions with China, has created a challenging investment landscape. Despite this downturn, select healthcare stocks show resilience by ...
-
What’s Happening With MRK Stock?
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per share, compared to the consensus estimates of $15.5...
-
What’s New With Merck?
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly stock (up 31%) and AbbVie stock (up 15%), ...
-
What’s Next For Merck Stock After An Upbeat Q3?
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share, compared to the consensus estimates of $16.5 billion ...
-
Why Did Merck Stock Rise 65%?
Merck stock (NYSE: MRK) has gained over 65% in value since early January 2021 – jumping from levels of $70 then to around $115 now – vs. an increase of about 50% for the S&P 500 over this period. This can primarily be attributed to a signif...
-
Is Merck Stock A Better Pick Over AbbVie?
We believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock (NYSE:ABBV). MRK stock trades at 14x forward earnings, versus 20x for ABBV. We think this gap in valuation will narrow in favor...
-
Should You Pick Merck Stock At $115 After A Q2 Beat?
Merck (NYSE: MRK) recently reported its Q2 results, with revenues and earnings exceeding our estimates . The company garnered $16.1 billion in revenue and adjusted earnings of $2.28 per share, compared to our estimates of $15.9 billion and $2....
